These immune system engagers (ISEr) comprise an immune stimulatory effector peptide and two binder peptides that bind selectively to cell-surface markers of tumor or tumor-associated cells, are synthetically accessible and do not activate cell-surface receptors (Fig. 1). This evidence concerns the gene CD177 and neoplasm.